In an increasingly interconnected global marketplace, understanding and adapting to the nuances of different markets is crucial for Market Access success. Our company supports pharma, biotech and medtech clients with Global Market Access and country-specific solutions in major markets such as the United States, France, Germany, Italy, Spain, Switzerland and the United Kingdom. Our agency Justin Stindt Consultants consists of experts with both Global Market Access expertise and local experience in all major markets. Our consultancy also has a broad network of local experts and partners in all major international markets to provide global solutions to our clients.
In each of these markets, our consulting firm leverages our expertise to tailor market access strategies that address specific challenges in each market while guaranteeing consistency with global strategy.
For more information on market access in a specific market (EU or US), click the links below:
Justin Stindt Consultants is your agency to support you with global Market Access
Justin Stindt Consultants is your consulting firm with experts who have extensive experience in Market Access in international markets. Our skilled consultants can help you with market access activities such as pricing and reimbursement strategies, funding pathways, early advice meetings, pricing negotiations, ad boards, early access programme feasibility assessments and dossier submissions, pricing and reimbursement dossier preparations and submissions etc.
For more information about the services our agency provides, go to Pricing & Reimbursement Strategy, Pricing & Reimbursement Dossiers, Payer & HTA Engagement.
MARKET ACCESS CONSULTANCY INDUSTRIES :
Pharmaceutical Market Access
The Pharma industry is characterized by long research & development cycles and complex Market Access, but once successful, medicines can achieve universal reimbursement.
Biotech
The biotech industry faces largely the same challenges & opportunities as the pharma industry but in addition to this financing rounds and Business Development & Licensing discussions play a pivotal role on the road towards successful Market Access.
Medical Devices
While regulatory approval is typically faster for Medical Devices compared to medicines, Pricing & Reimbursement is typically more complex and fragmented. Market Access for Medical Devices is a dynamic process which needs to be strategically managed throughout the product lifecycle.
e-Health / Digital Health
Market Access pathways for E-Health / Digital Health solutions are emerging and span from pilot projects to regular reimbursement pathways in key markets.
Our News
AIFA 2025 Annual Report: Key Insights into Italian Market Access, Pricing, and Pharma and Biotech Innovation
The Italian Medicines Agency has published their annual AIFA Activity Report in 2025, outlining the key facts and figures regarding pharma and biotech market access
Tariffs: Should Pharma and Biotech Manufacturers Relocate / Build Manufacturing in the U.S.?
As U.S. trade policy tightens, pharmaceutical and biotech companies face a pivotal strategic question: does it now make financial sense to manufacture in America? In
2025 German Pharma Industry and Market Access Key Facts and Figures
Germany: Europe’s Largest Pharma Market Germany is one of the key focus markets for pharma, biotech and medtech Market Access as it has the largest
Reshaping U.S. and Global Drug Pricing: What Pharma Needs to Know about MFN and tariffs in 2025
In an effort to combat the high prices for prescription drugs in the U.S., the Trump administration introduced a Most Favored Nation (MFN) drug pricing
Are Early Access Programmes the Better Funding Pathway for Biotechs?
Many biotech executives we currently meet report difficulties in securing their next financing round to fund further clinical development and bring their innovative treatments to
Navigating the DiGA Pathway in Germany in 2025: A Comprehensive Guide for MedTechs
What is DiGA in short? DiGA, short for Digitale Gesundheitsanwendungen, translates to Digital Health Applications in English. The DiGA pathway refers to the unique reimbursement